GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

Among the possibilities: Newly empowered Republicans could tweak the Medicare drug price negotiation program in ways that ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...

GSK confirmed this morning that the disappointing ... this month means that it will take the drug off the US market. The company said it has started the processing for withdrawing the marketing ...

In the life sciences industry in particular, leading pharma companies are already deploying this technology across their own operations to spur productivity and efficiency for mundane, time ...

Dividend announcements are not available. No other corporate actions details are available.